Tigecyklin Amarox

What Is Tigecyklin Amarox and What Is It Used For?

Tigecyklin Amarox is a glycylcycline antibiotic that works by inhibiting bacterial protein synthesis. It is indicated for complicated skin and soft tissue infections (cSSTI, except diabetic foot infection) and complicated intra-abdominal infections (cIAI) in adults and children aged 8 years and older when alternative antibiotics are considered unsuitable.

Tigecyklin Amarox contains tigecycline, the first approved member of the glycylcycline class of antibiotics. Glycylcyclines are structurally derived from the tetracycline scaffold by the addition of an N,N-dimethylglycylamido side chain at position 9 of the minocycline core. This chemical modification allows tigecycline to bypass the two main resistance mechanisms that limit older tetracyclines: tet-mediated efflux pumps and ribosomal protection proteins. The result is a molecule with potent activity against many organisms that are resistant to doxycycline, minocycline, and other earlier-generation tetracyclines.

Mechanistically, tigecycline binds with roughly five-fold greater affinity than tetracycline to the 30S ribosomal subunit of bacteria. By occupying the A-site of the ribosome, it prevents aminoacyl-tRNA molecules from docking and delivering amino acids to the growing peptide chain. Protein synthesis halts, bacterial growth stops, and the immune system has time to clear the infection. At the concentrations achieved in tissues, the effect is predominantly bacteriostatic, although bactericidal activity has been observed against certain streptococci.

The spectrum of activity of Tigecyklin Amarox is one of the broadest of any antibiotic currently marketed. It covers gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), penicillin-resistant Streptococcus pneumoniae, and group A streptococci. Gram-negative coverage extends to Escherichia coli, Klebsiella pneumoniae (including many ESBL- and some carbapenemase-producing strains), Enterobacter species, Acinetobacter baumannii, and Stenotrophomonas maltophilia. Anaerobic activity covers Bacteroides fragilis, Clostridium perfringens, and Peptostreptococcus. However, tigecycline has clinically insufficient activity against Pseudomonas aeruginosa, Proteus species, Providencia, and Morganella morganii, which intrinsically resist the drug through efflux.

Tigecyklin Amarox is licensed for two specific clinical scenarios. Complicated skin and soft tissue infections include deep abscesses, infected surgical wounds, infected burns, necrotising cellulitis, and soft tissue infection that has extended below the dermis into fascia or muscle and requires hospital-level care. Regulatory authorities specifically exclude diabetic foot infection from this indication because a randomised controlled trial failed to demonstrate non-inferiority of tigecycline against an ertapenem-based regimen in this population. Complicated intra-abdominal infections include perforated appendicitis, intra-abdominal abscesses, generalised peritonitis, post-surgical peritonitis, and complicated cholecystitis or cholangitis where infection has breached the anatomical boundaries of a single organ.

It is essential to understand that Tigecyklin Amarox is not a first-line antibiotic. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have highlighted that pooled analyses of phase III and IV clinical trials show a small but consistent increase in all-cause mortality in tigecycline-treated patients compared with those receiving comparator antibiotics. For this reason, modern antimicrobial stewardship programmes position tigecycline as a reserve agent, to be used only when microbiology, patient allergies, or intolerances rule out better-supported alternatives such as piperacillin-tazobactam, carbapenems, or linezolid.

What Should You Know Before Receiving Tigecyklin Amarox?

Before you receive Tigecyklin Amarox, tell your doctor about any allergies to tigecycline or to tetracycline-class antibiotics, any liver or biliary disease, bleeding disorders, pregnancy, breastfeeding, and any other medicines you are taking. Several important contraindications and precautions must be considered by the treating physician.

Because Tigecyklin Amarox is administered in hospital, your healthcare team will take a thorough medical and drug history before starting treatment. Be open about every prescription medicine, over-the-counter product, herbal supplement, and allergy you have, even if it seems minor. This information directly influences whether the benefit of tigecycline outweighs the risk for you.

Contraindications

Tigecyklin Amarox must not be used if you are hypersensitive (allergic) to tigecycline or to any of the other ingredients of the medicine (maltose monohydrate, hydrochloric acid, and sodium hydroxide). Because tigecycline is structurally related to tetracyclines such as doxycycline, minocycline, and lymecycline, patients with a documented allergy to any member of the tetracycline class should be considered at risk of cross-reactivity. The prescribing physician will weigh the severity of the previous reaction (urticaria versus anaphylaxis, for example) against the need for tigecycline and the availability of alternatives.

Warnings and Precautions

Several important safety considerations must be addressed before treatment begins. Inform your healthcare team if any of the following apply to you:

• Poor or delayed wound healing: Tigecycline has been associated with impaired wound healing in both clinical trials and post-marketing surveillance. If you have chronic wounds, recent major surgery, or a history of keloid scarring, your physician will weigh this risk carefully.
• Diarrhoea: New-onset diarrhoea during or after therapy can be a sign of Clostridioides difficile-associated colitis, a potentially severe and occasionally fatal complication of almost any antibiotic. Do not take anti-diarrhoeal medicines such as loperamide on your own; report symptoms to your doctor or nurse at once.
• Liver disease: Tigecycline is cleared predominantly via the bile. Patients with severe hepatic impairment (Child-Pugh C) accumulate the drug and require a reduced maintenance dose. Your physician will review baseline liver function and may request repeat testing during treatment.
• Biliary obstruction (cholestasis): Any condition that obstructs bile flow, such as gallstones in the common bile duct, primary biliary cholangitis, or a hepatic malignancy with biliary involvement, may alter tigecycline clearance and increase systemic exposure.
• Bleeding or coagulation disorders: Tigecycline prolongs prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalised ratio (INR). If you have haemophilia, take warfarin or a direct oral anticoagulant, or have recently had major surgery, your team will monitor clotting more closely.
• Pancreatic disease: Several cases of acute pancreatitis have been reported after initiation of tigecycline, sometimes within days of the first dose. Pre-existing pancreatitis, hypertriglyceridaemia, or heavy alcohol use may increase baseline risk.
• Tetracycline-class adverse effects: Effects known from tetracyclines — photosensitivity, hyperpigmentation, pseudotumour cerebri, or effects on growing bones and teeth — should also be considered theoretically possible with tigecycline.

Use in Children and Adolescents

Tigecyklin Amarox can be used in children aged 8 years and older, but only when no other suitable antibiotic is available. It must never be used in children under 8 years of age. Like all tetracycline-class antibiotics, tigecycline binds avidly to calcium in developing dental enamel and bone. Exposure during the period of tooth development (roughly from the second trimester of pregnancy through 8 years of age) can cause permanent yellow-grey-brown discoloration of the primary and permanent teeth and enamel hypoplasia. This effect is dose- and duration-dependent and is not reversible.

Pregnancy and Breastfeeding

Tigecyklin Amarox is potentially harmful to an unborn baby. Animal reproduction studies have shown reduced fetal weight, delayed ossification, and effects on bone and tooth development. Because the tetracycline class is known to cause skeletal and dental abnormalities in humans when used in the second or third trimester, Tigecyklin Amarox should be used during pregnancy only when the benefit clearly outweighs the potential risk and when safer alternatives are not available. If you become pregnant while receiving tigecycline, tell your doctor immediately.

It is not known to what extent tigecycline passes into human breast milk. Animal data suggest that the drug is excreted into milk, and the oral bioavailability of any tigecycline reaching a nursing infant would be very low. Nonetheless, a decision must be made whether to discontinue breastfeeding or to interrupt therapy, taking into account the importance of the medicine for the mother and the potential risks to the infant, including teeth and bone effects if absorbed.

Driving and Operating Machinery

Tigecycline can cause dizziness. Since the drug is only given in hospital, driving is not a practical concern during treatment. After discharge, if any residual dizziness persists, do not drive or operate heavy machinery until you feel completely well and your doctor confirms it is safe.

How Does Tigecyklin Amarox Interact with Other Drugs?

Tigecyklin Amarox can interact with anticoagulants (warfarin and related drugs), oral hormonal contraceptives, and calcineurin inhibitors such as tacrolimus and ciclosporin. Tigecycline is not a clinically important cytochrome P450 inhibitor or inducer. Always give your hospital team a complete and up-to-date medication list.

Tigecycline is not extensively metabolised by the liver; it is cleared primarily unchanged in the bile and, to a lesser degree, by the kidneys. As a result, classic cytochrome P450 drug-drug interactions are rare. Most clinically relevant interactions are pharmacodynamic (effects on blood coagulation or immunosuppressant exposure) rather than pharmacokinetic. However, a small number of interactions require specific attention and monitoring.

Major Interactions

Other Important Interactions

Because Tigecyklin Amarox is administered intravenously in a hospital, the pharmacy and clinical team will proactively screen your medication list for interactions. Patients should still disclose every product they take, including herbal remedies such as St John's wort, high-dose vitamin supplements, and any over-the-counter analgesics, to make the review complete.

What Is the Correct Dosage of Tigecyklin Amarox?

The standard adult dose is a 100 mg intravenous loading dose followed by 50 mg every 12 hours, each infused over 30 to 60 minutes. The usual treatment duration is 5 to 14 days. Severe liver impairment requires dose reduction; paediatric dosing is weight-based for children aged 8 to under 12 years.

Tigecyklin Amarox is supplied as a 50 mg powder for solution for infusion and must always be reconstituted and diluted before use. Administration is only ever performed by a doctor, nurse, or pharmacist in a healthcare facility, because accurate preparation, aseptic handling, and vein monitoring are essential for safety. Never attempt self-administration.

Adults

For patients with severe hepatic impairment (Child-Pugh C), the maintenance dose should be reduced to 25 mg every 12 hours after the initial 100 mg loading dose, reflecting reduced biliary clearance. No dose adjustment is required for mild to moderate hepatic impairment (Child-Pugh A or B), for any degree of renal impairment, or in elderly patients with normal organ function. Because tigecycline is not removed meaningfully by haemodialysis, no supplemental dose is needed around dialysis sessions.

Children and Adolescents

Children aged 8 to under 12 years receive a weight-based dose of 1.2 mg/kg body weight, infused intravenously every 12 hours over 30 to 60 minutes, with a maximum single dose of 50 mg. Adolescents aged 12 to under 18 years receive a fixed dose of 50 mg every 12 hours, mirroring adult maintenance dosing. No formal paediatric loading dose is defined in the approved product information; the decision to front-load is left to the treating infectious-disease specialist based on the severity of the infection and the weight of the patient.

Missed Dose

Because Tigecyklin Amarox is administered by trained staff in a hospital setting, missed doses are unusual. If a dose is accidentally delayed, the nursing team will document the delay and discuss the timing of subsequent doses with the prescriber. Usually the next dose is given as close as possible to the original schedule and spacing is maintained thereafter. Never a double dose to make up for a missed one.

Overdose

No specific human data are available on tigecycline overdose, and there is no antidote. In pre-clinical studies, very high intravenous doses produced nausea, vomiting, and laboratory abnormalities. If inadvertent overdose occurs, management is supportive: airway, breathing, circulation, close monitoring of vital signs, liver and renal function, and full blood count, and treatment of any symptoms that emerge. Because tigecycline is highly protein-bound and widely distributed into tissues, haemodialysis is not expected to remove meaningful amounts.

What Are the Side Effects of Tigecyklin Amarox?

The most frequent side effects are gastrointestinal — nausea, vomiting, and diarrhoea — affecting more than 1 in 10 patients. Common reactions include injection site reactions, dizziness, abdominal pain, and raised liver enzymes. Acute pancreatitis, liver failure, anaphylaxis, and Stevens-Johnson syndrome are rare but serious.

Like all medicines, Tigecyklin Amarox can cause side effects, although not everybody gets them. Side effects from clinical trials and post-marketing surveillance are grouped below by frequency categories defined by the European Union: very common (>1/10), common (1/100 to 1/10), uncommon (1/1,000 to 1/100), rare (1/10,000 to 1/1,000), and not known (cannot be estimated from available data). Report any new or worsening symptom promptly to your nursing team.

Antibiotic-associated colitis caused by Clostridioides difficile can occur with most antibiotics, including tigecycline. It presents with profuse, watery, sometimes bloody diarrhoea, abdominal cramping, fever, and a raised white blood cell count, and can develop during or up to two months after treatment. Severe cases require specific therapy with oral vancomycin, fidaxomicin, or faecal microbiota transplantation, and can rarely be fatal.

The FDA and EMA have both issued prescribing warnings regarding an increased risk of all-cause death observed in patients treated with tigecycline compared with comparator antibiotics in pooled trial analyses. The excess mortality signal was most pronounced in conditions for which tigecycline is not approved, particularly ventilator-associated pneumonia and diabetic foot infection. For its approved indications (cSSTI and cIAI) the signal is smaller but has not been fully explained, and it is the main reason why tigecycline is reserved for use when alternative antibiotics are not suitable.

How Should You Store Tigecyklin Amarox?

Unopened vials of Tigecyklin Amarox should be stored at controlled room temperature according to the information on the carton. After reconstitution, the solution should be used within 6 hours; once diluted in an infusion bag, it is stable for up to 24 hours at room temperature or 48 hours refrigerated at 2–8°C.

Because Tigecyklin Amarox is dispensed and handled by hospital pharmacies, storage is normally controlled by pharmacy staff and does not require patient action. However, the following parameters apply and are relevant if a patient, caregiver, or healthcare professional needs to understand the product life cycle:

• Unopened vials: Store according to the directions on the carton. The expiry date printed on the label refers to the last day of the indicated month. Do not use after this date.
• Reconstituted solution: After adding 5.3 mL of a compatible diluent (sodium chloride 0.9%, glucose 5%, or Ringer's Lactate), the solution is chemically and physically stable for up to 6 hours at 20–25 °C. For microbiological reasons, immediate use is recommended unless reconstitution has taken place under validated aseptic conditions.
• Diluted solution (in infusion bag): After further dilution for administration, the infusion is chemically and physically stable for up to 24 hours at 20–25 °C, or up to 48 hours when refrigerated at 2–8 °C. Of this 24- or 48-hour window, no more than 6 hours should be spent at room temperature including the infusion time.
• Visual inspection: The reconstituted solution should appear yellow to orange. A green or black colour, cloudiness, or particulate matter indicates product degradation; the preparation must be discarded and a fresh vial used.

Keep all medicines out of the sight and reach of children. Do not dispose of medicines via wastewater, household waste, or sharps bins other than those used by the healthcare facility. Unused preparations should be destroyed according to local pharmaceutical waste regulations to protect water and soil ecosystems from antimicrobial contamination. Tigecyklin Amarox is a single-use product; any remaining reconstituted or diluted solution must be discarded.

What Does Tigecyklin Amarox Contain?

Each vial of Tigecyklin Amarox contains 50 mg of tigecycline as the active substance. The inactive ingredients (excipients) are maltose monohydrate, hydrochloric acid (for pH adjustment), and sodium hydroxide (for pH adjustment). The product is an orange powder or cake that is reconstituted immediately before use.

Tigecyklin Amarox is supplied as a powder for concentrate for solution for infusion in a colourless type I glass vial closed with a rubber stopper and aluminium seal. Before reconstitution, the powder looks like an orange-coloured compact cake or lyophilisate. The excipients have specific pharmaceutical functions: maltose monohydrate acts as a bulking agent and lyoprotectant, preserving the structure of the active substance during freeze-drying; hydrochloric acid and sodium hydroxide are used in trace amounts to adjust the pH to the optimal range for stability (approximately pH 7.8).

The product is available in cartons of 1 or 10 vials. Not all pack sizes are necessarily marketed in every country. Each vial contains a slight overfill to compensate for residual volume, so that when correctly reconstituted with 5.3 mL of diluent and 5 mL is subsequently withdrawn, a full 50 mg of tigecycline is delivered to the patient.

Reconstitution and Preparation

The lyophilised powder is reconstituted by adding 5.3 mL of one of three compatible diluents: sodium chloride 9 mg/mL (0.9%) solution for injection, glucose 50 mg/mL (5%) solution for injection, or Ringer's Lactate solution. The vial is gently swirled until the drug dissolves completely, yielding a clear yellow-orange solution with a concentration of 10 mg/mL. Exactly 5 mL (50 mg) is then withdrawn and added to a 100 mL infusion bag of a compatible diluent, producing a final concentration of approximately 0.5 mg/mL that is ready for infusion.

For the initial 100 mg loading dose, two reconstituted vials are combined in a single 100 mL infusion bag to deliver the full dose in one infusion. When Tigecyklin Amarox is administered through a Y-site with other drugs, compatibility has been documented with (for example) amikacin, dobutamine, dopamine, gentamicin, haloperidol, lidocaine, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine, theophylline, and tobramycin in sodium chloride 0.9%. It must not be mixed in the same infusion line with drugs that have known incompatibilities, such as amphotericin B or diazepam.

The marketing authorisation holder is Amarox Pharma B.V., a generic pharmaceutical company based in the Netherlands. Manufacturing is performed at European Good Manufacturing Practice (GMP)-certified facilities, with quality release testing conducted in the EU. Because Tigecyklin Amarox is a generic medicinal product, it has demonstrated bioequivalence to the reference product and shares the same active ingredient, pharmaceutical form, strength, route of administration, and indications as branded tigecycline preparations.

Frequently Asked Questions About Tigecyklin Amarox